Neuronal Conditional Knockout of Collapsin Response Mediator Protein 2 Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis
Lin, Shao Xia
Feinstein, Douglas L
MetadataShow full item record
PublisherSAGE PUBLICATIONS LTD
CitationMoutal, A., Kalinin, S., Kowal, K., Marangoni, N., Dupree, J., Lin, S. X., … Feinstein, D. L. (2019). Neuronal Conditional Knockout of Collapsin Response Mediator Protein 2 Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis. ASN Neuro, 11, 175909141989209. https://doi.org/10.1177/1759091419892090
RightsCopyright © The Author(s) 2019. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/enus/nam/open-access-at-sage).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractWe previously showed that treatment with lanthionine ketimine ethyl ester (LKE) reduced disease severity and axonal damage in an experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis and increased neuronal maturation and survival in vitro. A major target of LKE is collapsin response mediator protein 2 (CRMP2), suggesting this protein may mediate LKE actions. We now show that conditional knockout of CRMP2 from neurons using a CamK2a promoter to drive Cre recombinase expression reduces disease severity in the myelin oligodendrocyte glycoprotein (MOG)35–55 EAE model, associated with decreased spinal cord axonal damage, and less glial activation in the cerebellum, but not the spinal cord. Immunohistochemical staining and quantitative polymerase chain reaction show CRMP2 depletion from descending motor neurons in the motor cortex, but not from spinal cord neurons, suggesting that the benefits of CRMP2 depletion on EAE may stem from effects on upper motor neurons. In addition, mice in which CRMP2 S522 phosphorylation was prevented by substitution for an alanine residue also showed reduced EAE severity. These results show that modification of CRMP2 expression and phosphorylation can influence the course of EAE and suggests that treatment with CRMP2 modulators such as LKE act in part by reducing CRMP2 S522 phosphorylation.
NoteOpen access journal
VersionFinal published version
SponsorsNational Multiple Sclerosis Society [RG-1501-02654]; US Department of Veteran Affairs [14S-RCS-003]; United States Department of Health & Human Services National Institutes of Health (NIH) - USA [1R01NS098772, 1R01DA042852]
- Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
- Authors: Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, Mun Aui P, Siatskas C, Litwak S, Fehlings MG, Strittmatter SM, Bernard CC
- Issue date: 2012 Jun
- Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia.
- Authors: Bannerman P, Hahn A, Soulika A, Gallo V, Pleasure D
- Issue date: 2007 Jan 1
- Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis.
- Authors: Dupree JL, Polak PE, Hensley K, Pelligrino D, Feinstein DL
- Issue date: 2015 Jul
- MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
- Authors: Mao P, Manczak M, Shirendeb UP, Reddy PH
- Issue date: 2013 Dec
- Changes in spinal cord stiffness in the course of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.
- Authors: Pyka-Fościak G, Zemła J, Lis GJ, Litwin JA, Lekka M
- Issue date: 2020 Feb 15